


IN THE CLAIMS:

1. (Currently Amended): A compound of the formula



wherein $n = 1-2$;

$m = 1-2$;

$o = 1-2$;

$X = O, S, \text{ or } NR^1$;

$Y = O, S, \text{ or } NR^1$;

R^1 is H, a straight chain or branched (C_1-C_8) alkyl, $C(=O)OR^6$, CH_2R^6 , $C(=O)NR^6R^7$, $C(=O)R^6$, or SO_2R^6 ;

Q is a straight chain or branched (C_2-C_8) alkenyl, a straight chain or branched (C_2-C_8) alkynyl, (C_3-C_8) cycloalkyl, (C_4-C_8) cycloalkenyl, 3-8 membered heterocycloalkyl, (C_5-C_{11}) bicycloalkyl, (C_7-C_{11}) bicycloalkenyl, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, (C_6-C_{11}) aryl or 5-12 membered heteroaryl; wherein Q is optionally substituted with one to six substituents R^2 independently selected from the group consisting of H, F, Cl, Br, I, cyano, CF_3 , $-NR^3R^4$, $-NR^3C(=O)R^4$, $-NR^3C(=O)NR^4R^5$, $-NR^3S(=O)_2R^4$, $-NR^3S(=O)_2NR^4R^5$, $-OR^3$, $-OC(=O)R^3$, $-OC(=O)OR^3$, $-OC(=O)NR^3R^4$, $-OC(=O)SR^3$, $-C(=O)OR^3$, $-C(=O)R^3$, $-C(=O)NR^3R^4$, $-SR^3$, $-S(=O)R^3$, $-S(=O)_2R^3$, $-S(=O)_2NR^3R^4$, and R^3 ;

each R^3 , R^4 , and R^5 is independently selected from the group consisting of H, straight chain or branched (C₁-C₈)alkyl, straight chain or branched (C₂-C₈)alkenyl, straight chain or branched (C₂-C₈)alkynyl, (C₃-C₈)cycloalkyl, (C₄-C₈)cycloalkenyl, (3-8 membered) heterocycloalkyl, (C₅-C₁₁)bicycloalkyl, (C₇-C₁₁)bicycloalkenyl, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, (C₆-C₁₁) aryl and 5-12 membered heteroaryl; wherein R^3 , R^4 , and R^5 , when not = H, are each independently optionally substituted with from one to six substituents, independently selected from the group consisting of F, Cl, Br, I, nitro, cyano, CF₃, -NR⁶R⁷, -NR⁶C(=O)R⁷, -NR⁶C(=O)NR⁷R⁸, -NR⁶S(=O)₂R⁷, -NR⁶S(=O)₂NR⁷R⁸, -OR⁶, -OC(=O)R⁶, -OC(=O)OR⁶, -OC(=O)NR⁶R⁷, -OC(=O)SR⁶, -C(=O)OR⁶, -C(=O)R⁶, -C(=O)NR⁶R⁷, -SR⁶, -S(=O)R⁶, -S(=O)₂R⁶, -S(=O)₂NR⁶R⁷, straight chain or branched (C₁-C₈)alkyl, straight chain or branched (C₂-C₈)alkenyl, straight chain or branched (C₂-C₈)alkynyl, (C₃-C₈)cycloalkyl, (C₄-C₈)cycloalkenyl, 3-8 membered heterocycloalkyl, (C₅-C₁₁)bicycloalkyl, (C₇-C₁₁)bicycloalkenyl, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, (C₆-C₁₁) aryl, 5-12 membered heteroaryl, and R⁶;

or, when R^3 and R^4 are as in NR³R⁴, they may instead optionally be connected to form with the nitrogen of NR³R⁴ to which they are attached a heterocycloalkyl moiety of from three to seven ring members, said heterocycloalkyl moiety optionally comprising one or two further heteroatoms independently selected from the group consisting of NR⁵, O, and S;

each R⁶, R⁷, and R⁸ is independently selected from the group consisting of H, straight chain or branched (C₁-C₈)alkyl, straight chain or branched (C₂-C₈)alkenyl, straight chain or branched (C₂-C₈)alkynyl, (C₃-C₈)cycloalkyl, (C₄-C₈)cycloalkenyl, 3-8 membered heterocycloalkyl, (C₅-C₁₁)bicycloalkyl, (C₇-C₁₁)bicycloalkenyl, 5-11 membered

heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, (C₆-C₁₁) aryl and (5-12 membered heteroaryl; wherein R⁶, R⁷, and R⁸ are each independently optionally substituted with from one to six substituents, independently selected from the group consisting of F, Cl, Br, I, nitro, cyano, CF₃, -NR⁹R¹⁰, -NR⁹C(=O)R¹⁰, -NR⁹C(=O)NR¹⁰R¹¹, -R⁹S(=O)₂R¹⁰, -NR⁹S(=O)₂NR¹⁰R¹¹, -OR⁹, -OC(=O)R⁹, -OC(=O)OR⁹, -OC(=O)NR⁹R¹⁰, -OC(=O)SR⁹, -C(=O)OR⁹, -C(=O)R⁹, -C(=O)NR⁶R⁷, -SR⁶, -S(=O)R⁶, -S(=O)₂R⁶, -S(=O)₂NR⁶R⁷, straight chain or branched (C₁-C₈)alkyl, straight chain or branched (C₂-C₈)alkenyl, straight chain or branched (C₂-C₈)alkynyl, (C₃-C₈)cycloalkyl, (C₄-C₈)cycloalkenyl, 3-8 membered heterocycloalkyl, (C₅-C₁₁)bicycloalkyl, (C₇-C₁₁)bicycloalkenyl, 5-11 membered heterobicycloalkyl, (5-11 membered) heterobicycloalkenyl, (C₆-C₁₁) aryl, (5-12 membered heteroaryl, and R⁹;

each R⁹, R¹⁰, and R¹¹ is independently selected from the group consisting of H, straight chain or branched (C₁-C₈)alkyl, straight chain or branched (C₂-C₈)alkenyl, straight chain or branched (C₂-C₈)alkynyl, (C₃-C₈)cycloalkyl, (C₄-C₈)cycloalkenyl, 3-8 membered heterocycloalkyl, (C₅-C₁₁)bicycloalkyl, (C₇-C₁₁)bicycloalkenyl, (5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, (C₆-C₁₁) aryl and 5-12 membered heteroaryl; with the proviso that when n is one, o is one, m is two, X is oxygen and Y is oxygen or NR¹, then Q cannot be unsubstituted phenyl or phenyl substituted only with one or more substituents selected from the group consisting of halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, (C₁-C₆) alkyl, (C₁-C₆) alkoxy, the group -OCH₂O- attached to both the meta and para positions of the phenyl ring, the group -CH₂CH₂CH₂CH₂- attached to both the meta and para positions of the phenyl ring, and phenoxy or phenyl wherein said phenyl and the phenyl moiety of said phenoxy can optionally be substituted with

one or more substituents selected from the group consisting of halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, (C₁-C₆) alkyl, and (C₁-C₆) alkoxy; or an enantiomeric, diastereomeric, and tautomeric isomer of such compound, or a pharmaceutically acceptable salt of such compound or isomer.

2. (Original): A compound according to claim 1, wherein X = O and Y = O or NH.

3. (Original): A compound according to claim 1, wherein Y = O.

4. (Original): A compound according to claim 1, wherein R¹ = methyl.

5. (Original): A compound according to claim 1, wherein m = 2, o = 1 and n = 1.

6. (Previously Presented): A compound according to claim 1, wherein Q is (C₆-C₁₁)aryl that is optionally substituted with from one to five substituents independently selected from the group consisting of H, F, Cl, Br, I, cyano, CF₃, -NR³R⁴, -NR³C(=O)R⁴, -NR³C(=O)NR⁴R⁵, -NR³S(=O)₂R⁴, -NR³S(=O)₂NR⁴R⁵, -OR³, -OC(=O)R³, -OC(=O)OR³, -OC(=O)NR³R⁴, -OC(=O)SR³, -C(=O)OR³, -C(=O)R³, -C(=O)NR³R⁴, -SR³, -S(=O)R³, -S(=O)₂R³, -S(=O)₂NR³R⁴, straight chain or branched (C₁-C₈)alkyl, straight chain or branched (C₂-C₈)alkenyl, straight chain or branched (C₂-C₈)alkynyl, (C₃-C₈)cycloalkyl, (C₄-C₈)cycloalkenyl, 3-8 membered heterocycloalkyl, (C₅-C₁₁)bicycloalkyl, (C₇-C₁₁)bicycloalkenyl, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, (C₆-C₁₁) aryl, and 5-12 membered heteroaryl.

7. (Previously Presented): A compound according to claim 1, wherein R^3 is (C₆-C₁₁)aryl or (5-12 membered) heteroaryl that is optionally substituted with from one to five substituents independently selected from the group consisting of H, F, Cl, Br, I, nitro, cyano, CF₃, -NR⁶R⁷, -NR⁶C(=O)R⁷, -NR⁶C(=O)NR⁷R⁸, -NR⁶S(=O)₂R⁷, -NR⁶S(=O)₂NR⁷R⁸, -OR⁶, -OC(=O)R⁶, -OC(=O)OR⁶, -OC(=O)NR⁶R⁷, -OC(=O)SR⁶, -C(=O)OR⁶, -C(=O)R⁶, -C(=O)NR⁶R⁷, -SR⁶, -S(=O)R⁶, -S(=O)₂R⁶, -S(=O)₂NR⁶R⁷, straight chain or branched (C₁-C₈)alkyl, straight chain or branched (C₂-C₈)alkenyl, straight chain or branched (C₂-C₈)alkynyl, (C₃-C₈)cycloalkyl, (C₄-C₈)cycloalkenyl, (3-8 membered) heterocycloalkyl, (C₅-C₁₁)bicycloalkyl, (C₇-C₁₁)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (5-11 membered) heterobicycloalkenyl, (C₆-C₁₁) aryl, (5-12 membered) heteroaryl, and R⁶.

8. (Original): A pharmaceutical composition for the treatment of schizophrenia in a mammal, comprising an amount of a compound according to claim 1 that is effective in treating schizophrenia and a pharmaceutically acceptable carrier.

9. (Original): A method of treating schizophrenia in a mammal, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating schizophrenia.

10. (Original): A pharmaceutical composition for the treatment of schizophrenia in a mammal, comprising an $\alpha 7$ nicotinic receptor agonizing amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

11. (Original): A method of treating schizophrenia in a mammal, comprising administering to said mammal an $\alpha 7$ nicotinic receptor agonizing amount of a compound according to claim 1.

12. (Currently Amended): A pharmaceutical composition for treating a disorder or condition selected from the group consisting of inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis, cognitive dysfunction, tinnitus, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbituates, opioids or cocaine), headache, stroke, traumatic brain injury, psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, HIV induced dementia, senile dementia of the Alzheimer's type, Parkinson's disease, attention deficit hyperactivity disorder and Tourette's Syndrome in a mammal, comprising an amount of a compound according to claim 1 that is effective in treating such disorder or condition and a pharmaceutically acceptable carrier.

13. (Currently Amended): A method of treating in a mammal in need thereof a disorder or condition selected from the group consisting of inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel

syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis, cognitive dysfunction, tinnitus, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbituates, opioids or cocaine), headache, stroke, traumatic brain injury, psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, HIV induced dementia, senile dementia of the Alzheimer's type, Parkinson's disease, attention deficit hyperactivity disorder and Tourette's Syndrome, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating such disorder or condition.

14. (Currently Amended): A pharmaceutical composition for treating a disorder or condition selected from the group consisting of inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis, cognitive dysfunction, tinnitus, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbituates, opioids or cocaine), headache, stroke, traumatic brain injury, psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, multi-infarct

dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, HIV induced dementia, senile dementia of the Alzheimer's type, Parkinson's disease, attention deficit hyperactivity disorder and Tourette's Syndrome in a mammal, comprising an $\alpha 7$ nicotinic receptor agonizing amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

15. (Currently Amended): A method of treating in a mammal in need thereof a disorder or condition selected from the group consisting of inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis, cognitive dysfunction, tinnitus, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbituates, opioids or cocaine), headache, stroke, traumatic brain injury, psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, multi-infarct dementia, age related cognitive decline, epilepsy, including petit mal absence epilepsy, HIV induced dementia, senile dementia of the Alzheimer's type, Parkinson's disease, attention deficit hyperactivity disorder and Tourette's Syndrome, comprising administering to said mammal an $\alpha 7$ nicotinic receptor agonizing amount of a compound according to claim 1.

16. (Previously Presented): A compound according to claim 1 selected from the group consisting of:

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-pyridin-2-yl-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-pyridin-3-yl-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-pyridin-4-yl-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 2-nitro-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid naphthalen-2-yl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carbothioic acid O-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-methoxycarbonyl-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 6-bromo-naphthalen-2-yl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid methyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid isobutyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid pyridin-2-yl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid pyridin-3-yl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid octyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-benzyloxy-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-methylsulfanyl-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-indan-1-yl-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-furan-3-yl-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-(6-fluoro-pyridin-3-yl)-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-benzoyl-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-benzyl-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-imidazol-1-yl-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-benzoyloxy-phenyl ester;
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-[1,2,4]triazol-1-yl-phenyl ester;
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-(4-acetyl-piperazin-1-yl)-phenyl ester;
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 2-benzooxazol-2-yl-phenyl ester;
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 2-benzothiazol-2-yl-phenyl ester;
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 2-benzyl-phenyl ester;
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 3-benzoyl-phenyl ester;
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-(5-ethoxycarbonyl-pyridin-3-yl)-phenyl ester;
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-(6-methyl-pyridin-2-yl)-phenyl ester;
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-(3,5-dimethyl-isoxazol-4-yl)-phenyl ester;
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-(4-methyl-pyridin-2-yl)-phenyl ester;
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-(5-carbamoyl-pyridin-3-yl)-phenyl ester;
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-(5-cyano-pyridin-3-yl)-phenyl ester;
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-imidazo[1,2-a]pyridin-3-yl-phenyl ester;
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid ethyl ester;
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid propyl ester; and
 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 3-pyridin-3-yl-phenyl ester; and
 pharmaceutical acceptable salts thereof.

17. (Previously Presented): A compound according to claim 1 selected from the group consisting of:

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid (4-bromo-phenyl)amide;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-cyano-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-iodo-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 2'-methoxy-biphenyl-4-yl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 3'-methoxycarbonyl-biphenyl-4-yl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-tert-butyl-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-trifluoromethyl-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 2-chloro-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 2-iodo-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4'-cyano-biphenyl-4-yl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4'-bromo-biphenyl-4-yl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 2-trifluoromethyl-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 3-fluoro-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 3-chloro-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 3-bromo-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 3-tert-butyl-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 3-iodo-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 3-phenoxy-phenyl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 3'-methyl-biphenyl-4-yl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4'-chloro-biphenyl-4-yl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 2'-methyl-biphenyl-4-yl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 2'-chloro-biphenyl-4-yl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 3'-chloro-biphenyl-4-yl ester;

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 3'-cyano-biphenyl-4-yl ester;
1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4'-methoxy-biphenyl-4-yl ester;
1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid biphenyl-3-yl ester;
1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-bromo-3,5-dimethyl-phenyl ester;
1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-bromo-3-methyl-phenyl ester;
1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-bromo-3-chloro-phenyl ester; and
1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 3,4-dimethyl-phenyl ester and;
pharmaceutically acceptable salts thereof.

18. (Previously Presented): A compound according to claim 1 selected from the group consisting of:

1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 2',5'-dimethyl-biphenyl-4-yl ester;
1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 3',5'-dimethyl-biphenyl-4-yl ester;
1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 2',3'-dimethyl-biphenyl-4-yl ester; and
pharmaceutically acceptable salts thereof.

19. (Original): A compound according to claim 1 that is 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-cyclohexyl-phenyl ester or a pharmaceutically acceptable salt thereof.

20. (Original): A compound according to claim 1 that is 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-bromo-phenyl ester or a pharmaceutically acceptable salt thereof.